Nightingale Health aktie (HEALTH) | Pressmeddelande

Nightingale Health’s laboratory implementation in the United States progresses as planned – opens first to medical research customers in Summer 2025

Nightingale Health Plc

Trading in Nightingale Health’s B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US

Nightingale Health Plc’s listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025

Nightingale Health Plc’s listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will...

Cision • 18 Mar 10:30

The Finnish Financial Supervisory Authority has approved Nightingale Health Plc’s Finnish prospectus

Cision • 17 Mar 15:15

Nightingale Health establishes ADR program in the US – trading in Company’s B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US

Nightingale Health establishes ADR program in the US – trading in Company’s B shares and ADRs begins on 19 March 2025, at the earliest, and ...

Cision • 17 Mar 12:55

Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki

Cision • 12 Mar 13:30

Nightingale Health’s half-year report: International expansion continues in Southeast Asia and the United States

Cision • 06 Mar 08:00

Nightingale Health to publish half-year report for July – December 2024 on 6 March 2025

Cision • 28 Feb 11:35

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risk...

Cision • 27 Feb 13:15

Nightingale Health announces its updated regulatory plan in the United States

Cision • 07 Feb 13:15

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Cision • 27 Jan 08:00

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the...

Cision • 23 Jan 10:00

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the pro...

Cision • 04 Dec 2024 09:00

Nightingale Health announces opening of its Singapore laboratory

Cision • 29 Nov 2024 10:30

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OT...

Cision • 27 Nov 2024 13:20

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Sing...

Cision • 14 Nov 2024 08:15

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Cision • 08 Nov 2024 16:00

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Cision • 06 Nov 2024 08:45

Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale’s Health Check in the US

Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use o...

Cision • 30 Oct 2024 08:35

Notice to the Annual General Meeting of Nightingale Health Plc

Cision • 10 Oct 2024 12:00

Nightingale Health’s Annual Report for financial year 2023–2024 has been published

Cision • 10 Oct 2024 08:00

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Cision • 09 Oct 2024 13:30

Nightingale Health’s Board of Directors resolved on amendment to CEO’s incentive program

Cision • 20 Sep 2024 12:45

Nightingale Health Plc Financial Statements Release 1 July 2023 – 30 June 2024

Cision • 20 Sep 2024 08:00

Nightingale Health receives third regulatory approval for healthcare use from Health Sciences Authority in Singapore

Cision • 19 Sep 2024 12:00

Nightingale Health to publish Financial Statements Release for financial year July 2023 – June 2024 on 20 September 2024

Cision • 05 Sep 2024 13:30

Nightingale Health attains UKCA marking for its blood analysis technology to bring its technology to healthcare use in the United Kingdom

Cision • 20 Aug 2024 08:45

Nightingale Health receives additional regulatory approval for healthcare use from Health Sciences Authority in Singapore

Cision • 20 Aug 2024 08:15

Nightingale Health and U.S.-based Phenome Health announce a partnership to strive towards the most transformational change in the history of healthcare

Nightingale Health and U.S.-based Phenome Health announce a partnership to strive towards the most transformational change in the history of...

Cision • 06 Aug 2024 17:00

Nightingale Health Plc – Managers’ transactions – Olli Karhi

Cision • 04 Jul 2024 13:35

Summary of Financial Year 7/2023 - 6/2024: Nightingale Health achieved several breakthroughs in adopting the company’s technology in healthcare

Summary of Financial Year 7/2023 - 6/2024: Nightingale Health achieved several breakthroughs in adopting the company’s technology in healthc...

Cision • 03 Jul 2024 15:35

Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel

Cision • 28 Jun 2024 13:00

Inside information: Nightingale Health and Boston Heart Diagnostics enter strategic partnership to sell Nightingale’s Health Check in the United States

Inside information: Nightingale Health and Boston Heart Diagnostics enter strategic partnership to sell Nightingale’s Health Check in the Un...

Cision • 28 Jun 2024 08:35

Nightingale Health and ZOE expand research collaboration to include self-collected blood samples

Cision • 27 Jun 2024 15:15

Nightingale Health acquires all intellectual property assets of the Velvet™ blood collection device and secures its position as the sole provider of a fully integrated remote health check solution

Nightingale Health acquires all intellectual property assets of the Velvet™ blood collection device and secures its position as the sole pro...

Cision • 27 Jun 2024 13:45

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Cision • 18 Jun 2024 16:25

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Pasi Soininen)

Cision • 18 Jun 2024 16:15

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna)

Cision • 18 Jun 2024 16:05

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas)

Cision • 18 Jun 2024 14:20

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Cision • 11 Jun 2024 13:50

Health check based on advanced blood analysis technology builds a better foundation for public health

Cision • 06 Jun 2024 08:30

Nightingale Health’s Board of Directors extended the subscription period of employee option rights

Cision • 23 May 2024 09:45

Nightingale Health launches new website aligned with the B2B and B2G strategy

Cision • 21 May 2024 10:15

Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million

Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research...

Cision • 25 Apr 2024 10:50

Nightingale Health to establish a laboratory in the United States with Weill Cornell Medicine as the first customer

Cision • 16 Apr 2024 07:45

Supplement to the release: Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc.

Supplement to the release: Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundati...

Cision • 12 Apr 2024 11:45

Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc.

Cision • 12 Apr 2024 06:15

Nightingale Health has completed the acquisition of Welltus Inc

Cision • 29 Mar 2024 08:00

Correction: Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Cision • 21 Mar 2024 05:50

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Cision • 20 Mar 2024 16:00

Nightingale Health’s technology used to analyze Uganda’s General Population Cohort (GPC)

Cision • 19 Mar 2024 07:00

Supplement to the release: Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc

Cision • 07 Mar 2024 14:30

Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc

Cision • 07 Mar 2024 08:00

Nightingale Health’s Half-year report: Healthcare implementations progressing in Finland and Singapore

Cision • 07 Mar 2024 07:00

Nightingale Health to publish half-year report for July – December 2023 on 7 March 2024

Cision • 28 Feb 2024 13:15

Nightingale Health receives regulatory approval for healthcare use from Health Sciences Authority in Singapore

Cision • 23 Feb 2024 08:00

Nightingale Health receives five new patents for its proprietary health risk detection capability

Cision • 31 Jan 2024 07:00

Nightingale Health joins Radical Health Festival Helsinki as Founding Partner to promote urgent global need for preventative health

Cision • 19 Jan 2024 09:00

Terveystalo begins using Nightingale Health’s blood analysis technology in regular health checks in occupational health

Cision • 02 Jan 2024 08:45

Nightingale Health completes the analysis of all 500,000 UK Biobank samples creating the world's largest blood biomarker database for chronic disease research and prevention

Nightingale Health completes the analysis of all 500,000 UK Biobank samples creating the world's largest blood biomarker database for chroni...

Cision • 13 Dec 2023 07:30

Change in Nightingale Health Plc’s Management Team

Cision • 27 Nov 2023 17:00

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Cision • 16 Nov 2023 16:30

Inside information: Nightingale Health and Innoquest Diagnostics enter into collaboration agreement to make Nightingale Health’s technology accessible in the Southeast Asia region

Inside information: Nightingale Health and Innoquest Diagnostics enter into collaboration agreement to make Nightingale Health’s technology ...

Cision • 15 Nov 2023 08:15

Research study abstract by Nightingale Health on heart disease prevention wins American Heart Association’s Paul Dudley White International Scholar Award

Research study abstract by Nightingale Health on heart disease prevention wins American Heart Association’s Paul Dudley White International ...

Cision • 01 Nov 2023 09:45

Notice to the Annual General Meeting of Nightingale Health Plc

Cision • 19 Oct 2023 14:00

Nightingale Health’s Annual Report for financial year 2022–2023 has been published

Cision • 19 Oct 2023 08:00

Nightingale Health Plc – Managers’ transactions – Ilkka Laurila

Cision • 17 Oct 2023 09:15

Nightingale Health’s Board of Directors resolved on new share-based incentive programs and amendments to existing incentive programs

Cision • 16 Oct 2023 14:00

Nightingale Health Plc – Managers’ transactions – Tuukka Paavola

Cision • 02 Oct 2023 08:30

Nightingale Health Plc Financial Statements Release 1 July 2022 – 30 June 2023

Cision • 28 Sep 2023 08:00

Nightingale Health receives three new patents further strengthening its IP portfolio

Cision • 26 Sep 2023 08:00

Nightingale Health’s laboratory in the United Kingdom to be situated in Porton Science Park

Cision • 19 Sep 2023 09:15

Nightingale Health to publish Financial Statements Release for financial year July 2022–June 2023 on 28 September 2023

Cision • 14 Sep 2023 13:30

Inside information: Nightingale Health updates its strategy with a focus on B2B and B2G markets

Cision • 11 Sep 2023 11:30

Nightingale Health to provide blood sample analysis service for a large U.S. healthcare system

Nightingale Health to provide blood sample analysis service for a large U.

Cision • 06 Sep 2023 07:30

Inside information: Terveystalo adopts Nightingale Health’s blood analysis technology in regular health checks in occupational health

Cision • 30 Aug 2023 17:35

Nightingale Health rolls out remote blood collection kit for medical research and clinical trials

Cision • 17 Aug 2023 08:55

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Cision • 06 Jul 2023 15:00

Inside information: Update on Nightingale Health Plc’s business targets for financial year 2022 – 2023

Cision • 03 Jul 2023 10:00

Inside information: Nightingale Health and Terveystalo sign letter of intent to expand strategic partnership

Cision • 30 Jun 2023 10:20

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2023 – 2024

Cision • 31 May 2023 08:30

Nightingale Health has received six patent approvals for its proprietary health risk detection platform

Cision • 23 May 2023 08:00

Maximilian LeRoux appointed as Chief Commercial Officer of Nightingale Health Plc

Cision • 08 May 2023 10:45

Nightingale Health Plc: Resolutions of the Extraordinary General Meeting and the Board of Directors’ organizational meeting

Cision • 24 Apr 2023 16:10

Nightingale Health Plc’s Auditor to Change

Cision • 24 Mar 2023 09:00

Nightingale Health Group’s Half-year report 1 July 2022 – 31 December 2022: Commercialization progressing in line with strategy

Cision • 23 Mar 2023 08:00

Nightingale Health Plc: Unaudited financial information in accordance with IFRS for the comparative half-year periods

Cision • 22 Mar 2023 11:00

Notice to the Extraordinary General Meeting of Nightingale Health Plc

Cision • 17 Mar 2023 11:15

Nightingale Health Plc – Managers’ transactions – Olli Karhi

Cision • 14 Feb 2023 16:40

Nightingale Health combines genetics with its unique blood test results in Livit by Nightingale Health service

Cision • 03 Feb 2023 08:00

Inside information: Nightingale Health acquires worldwide license for blood self-collection device Velvet™

Cision • 31 Jan 2023 15:05

Nightingale Health to open laboratory in the United Kingdom in 2023

Cision • 25 Jan 2023 07:00

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Cision • 22 Dec 2022 15:15

Nightingale Health Plc – Managers’ transactions – Leena Niemistö

Cision • 29 Nov 2022 08:45

Nightingale Health Plc – Managers’ transactions – Leena Niemistö

Cision • 29 Nov 2022 08:45

Change in the publication date of Nightingale Health Plc’s half-year financial report for the period 1 July – 31 December 2022

Cision • 17 Nov 2022 17:20

Börskollen

För dig med koll på börsen

Pressmeddelanden från Nightingale Health

Nightingale Health’s laboratory implementation in the United States progresses as planned – opens first to medical research customers in Summer 2025

Trading in Nightingale Health’s B shares and ADRs begins on 21 March 2025 on the OTCQX International Market in the US

Nightingale Health Plc’s listing application has been approved and trading in its Series B shares on the Main Market of Nasdaq Helsinki will commence on 19 March 2025

The Finnish Financial Supervisory Authority has approved Nightingale Health Plc’s Finnish prospectus

Nightingale Health establishes ADR program in the US – trading in Company’s B shares and ADRs begins on 19 March 2025, at the earliest, and 24 March 2025, at the latest, on the OTCQX Market in the US

Nightingale Health Plc applies for its series B shares to be listed on the Main Market of Nasdaq Helsinki

Nightingale Health’s half-year report: International expansion continues in Southeast Asia and the United States

Nightingale Health to publish half-year report for July – December 2024 on 6 March 2025

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health Plc appoints Lago Kapital as liquidity provider

Nightingale Health Plc: Subscription of Series B shares with option rights

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Nightingale Health announces opening of its Singapore laboratory

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.

Nightingale Health Asia achieves ISO 13485:2016 certification and completes regulatory readiness to launch its blood testing service in Singapore

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health and Boston Heart Diagnostics have successfully completed their pilot and move to the production phase expanding the use of Nightingale’s Health Check in the US

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health’s Annual Report for financial year 2023–2024 has been published

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Nightingale Health’s Board of Directors resolved on amendment to CEO’s incentive program

Nightingale Health Plc Financial Statements Release 1 July 2023 – 30 June 2024

Nightingale Health receives third regulatory approval for healthcare use from Health Sciences Authority in Singapore

Nightingale Health to publish Financial Statements Release for financial year July 2023 – June 2024 on 20 September 2024

Nightingale Health attains UKCA marking for its blood analysis technology to bring its technology to healthcare use in the United Kingdom

Nightingale Health receives additional regulatory approval for healthcare use from Health Sciences Authority in Singapore

Nightingale Health and U.S.-based Phenome Health announce a partnership to strive towards the most transformational change in the history of healthcare

Nightingale Health Plc – Managers’ transactions – Olli Karhi

Summary of Financial Year 7/2023 - 6/2024: Nightingale Health achieved several breakthroughs in adopting the company’s technology in healthcare

Inside Information: 23andMe and Nightingale Health Announce Strategic Collaboration to Pilot Blood Biomarker Panel

Inside information: Nightingale Health and Boston Heart Diagnostics enter strategic partnership to sell Nightingale’s Health Check in the United States

Nightingale Health and ZOE expand research collaboration to include self-collected blood samples

Nightingale Health acquires all intellectual property assets of the Velvet™ blood collection device and secures its position as the sole provider of a fully integrated remote health check solution

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Pasi Soininen)

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Teemu Suna)

Disclosure under Chapter 9, Section 10 of the Securities Markets Act (Antti Kangas)

Conversion of Nightingale Health Plc’s Series A shares to Series B shares

Health check based on advanced blood analysis technology builds a better foundation for public health

Nightingale Health’s Board of Directors extended the subscription period of employee option rights

Nightingale Health launches new website aligned with the B2B and B2G strategy

Inside information: Nightingale Health achieves one of its business targets for this financial year by winning contracts in medical research with a total contract value of at least EUR 3.2 million

Nightingale Health to establish a laboratory in the United States with Weill Cornell Medicine as the first customer

Supplement to the release: Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc.

Inside Information: Nightingale Health enters into agreement to analyze 50,000 blood samples with Kaiser Foundation Health Plan, Inc.

Nightingale Health has completed the acquisition of Welltus Inc

Correction: Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Conversion of Nightingale Health Plc’s EMP shares to Series B shares

Nightingale Health’s technology used to analyze Uganda’s General Population Cohort (GPC)

Supplement to the release: Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc

Inside information: Nightingale Health strengthens its Japan business by acquiring Welltus Inc

Nightingale Health’s Half-year report: Healthcare implementations progressing in Finland and Singapore

Nightingale Health to publish half-year report for July – December 2023 on 7 March 2024

Nightingale Health receives regulatory approval for healthcare use from Health Sciences Authority in Singapore

Nightingale Health receives five new patents for its proprietary health risk detection capability

Nightingale Health joins Radical Health Festival Helsinki as Founding Partner to promote urgent global need for preventative health

Terveystalo begins using Nightingale Health’s blood analysis technology in regular health checks in occupational health

Nightingale Health completes the analysis of all 500,000 UK Biobank samples creating the world's largest blood biomarker database for chronic disease research and prevention

Change in Nightingale Health Plc’s Management Team

Resolutions of the Annual General Meeting and the Board of Directors’ organizational meeting of Nightingale Health Plc

Inside information: Nightingale Health and Innoquest Diagnostics enter into collaboration agreement to make Nightingale Health’s technology accessible in the Southeast Asia region

Research study abstract by Nightingale Health on heart disease prevention wins American Heart Association’s Paul Dudley White International Scholar Award

Notice to the Annual General Meeting of Nightingale Health Plc

Nightingale Health’s Annual Report for financial year 2022–2023 has been published

Nightingale Health Plc – Managers’ transactions – Ilkka Laurila

Nightingale Health’s Board of Directors resolved on new share-based incentive programs and amendments to existing incentive programs

Nightingale Health Plc – Managers’ transactions – Tuukka Paavola

Nightingale Health Plc Financial Statements Release 1 July 2022 – 30 June 2023

Nightingale Health receives three new patents further strengthening its IP portfolio

Nightingale Health’s laboratory in the United Kingdom to be situated in Porton Science Park

Nightingale Health to publish Financial Statements Release for financial year July 2022–June 2023 on 28 September 2023